It has been recently revealed that the second largest private medical insurance company in the UK has changed its opinion on Abiraterone, a drug used to treat patients suffering from advanced prostate cancer.

Axa PPP has announced that it would be providing medical insurance cover for the drug and would be paying for it. Confirming the news Axa PPP spokesperson said that they have gone in line with Bupa and WPA as they think that it would be right thing to do.

The company is the latest entrant in the list of policy insurance companies which provide insurance for the drug. Another two companies which provide Abiraterone are Bupa and WPA. Both of the companies pay £3,000 a month for a single patient.

Dr. Annabel Bentley, who is the Medical Director of Bupa Health and Wellbeing, said, "Bupa routinely funds abiraterone for members whose prostate cancer has spread. We fund cancer treatments for as long they are needed and we do not apply cost or time limits".

Bentley further affirmed that for them nothing is more important than their patients. He said that Bupa follows a simple policy which is that if a drug is being licensed by the EMA (European Medicines Agency) then it has to be a safe drug. They make sure that they provide every EMA licensed drug irrespective of its cost.

There is no doubt that the drug is effective. Its trial has proved that the drug extends patients lives by another four months which no other drug could do. The only problem is that it is too expensive and same reason has got highlighted in a draft decision being issued by the National Institute for Health and Clinical Excellence (Nice).

Availability of the drug with Axa PPP would help patients suffering from last stage prostate cancer, said the company spokesperson.